Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
LL-37: Regulatory Status
Current legal and regulatory status for LL-37 across jurisdictions. This page reflects the most recent verified information and is updated as regulatory actions occur.
Back to LL-37 overviewUnited States
⚗
Research Only
Compounding status: restricted — Category 2 (remains restricted as of March 2026). WADA: not listed. no regulatory approval in any jurisdiction; limited clinical development programs
Last verified:
What This Means
Reclassification is not the same as FDA approval.
Even if LL-37 moves to Category 1, it remains an off-label therapeutic that requires physician supervision. Category 1 means it can be compounded under section 503A — it does not confer approved-drug status.